基于《药品管理法》修订的药品违法与侵权行为条款修改建议

中国药物警戒 ›› 2015, Vol. 12 ›› Issue (3): 150-155.

基于《药品管理法》修订的药品违法与侵权行为条款修改建议

李名石,杨悦*

沈阳药科大学工商管理学院，辽宁沈阳 110016

收稿日期:2015-02-10 出版日期:2015-03-08 发布日期:2015-07-28
通讯作者: 杨悦，女，教授?博导，药事法规与药品政策。
作者简介:李名石，女，在读硕士，药事法规与药品政策。

Legislative Proposals of the Drug Illegal Acts and Torts Based on the Revise of the Drug Administration Law of PRC

LI Ming-shi,YANG Yue*

School of Business Administration, Shenyang Pharmaceutical University, Liaoning Shenyang 110016, China

Received:2015-02-10 Online:2015-03-08 Published:2015-07-28

摘要/Abstract

摘要： 目的比较美欧药品违法行为与侵权行为的法律界定、法律责任，以期为构建我国药品责任法律制度提供参考和理论依据。方法采用文献研究和比较研究方法，探讨药品违法和侵权行为的在不同法律中设定的方式与联系，以及法律责任设定。结果药品违法与侵权行为分属行政规制与产品责任、民事侵权，目前，我国《药品管理法》关注药品质量约束机制和行政合规性，而《产品质量法》和《侵权责任法》缺乏有效衔接的侵权责任制度。同时，缺陷界定存在瑕疵，假劣药划分交叉混乱，赔偿责任设定未将行为人主观恶意程度和造成的损害后果作为特殊考量因素，致使司法实践和执法操作存在诸多适用难题。结论以药品管理法修订为契机，对药品违法与产品责任、侵权行为进行关联性条款设定，维护公众用药合法权益。

关键词: 药品违法行为, 假劣药, 药品侵权行为, 法律修订

Abstract: Objective To compare the definitions, legal liabilities of drug illegal acts and torts in US and Europe, so as to provide reference for building drug responsibility legal system in our country. Methods Using the method of literature study and comparative study, this paper discusses the drug illegal acts and torts in different laws. Results Illegal acts and torts refer to administrative regulation and product liability, at present, the Drug Administration Law in our country pays close attention to drug quality constraint mechanism and administrative compliance, but Product Quality Law and Tort Law are Lack of effective connect of liability system. At the same time, the definitions of defect and illegal acts are imperfect, and the compensation doesn't consider the badness degree of the illegal behavior and the damage consequence. So there are many problems in the judicial practice and law enforcement operations. Conclusion Our country should take steps to define drug illegal acts and torts clearly, revise the regulations to guide the management of drugs, to make sure of the safety of public health.

Key words: drug illegal acts, counterfeit drugs, torts, law revision

中图分类号:

R951

李名石,杨悦. 基于《药品管理法》修订的药品违法与侵权行为条款修改建议[J]. 中国药物警戒, 2015, 12(3): 150-155.

LI Ming-shi,YANG Yue. Legislative Proposals of the Drug Illegal Acts and Torts Based on the Revise of the Drug Administration Law of PRC[J]. Chinese Journal of Pharmacovigilance, 2015, 12(3): 150-155.

参考文献

[1] Federal Food, Drug, and Cosmetic Act(FD&C Act). Chapter II §321- Definitions; generally(g)(2)[S/OL]. (1938-01-25)[2014-10-27].http://www.gpo.gov/fdsys/pkg/USCODE-2010-title21/html/USCODE-2010-title21-chap9-subchapII.htm.
[2] Federal Food, Drug, and Cosmetic Act (FD&C Act). Chapter V §351Adulterated drugs and devices [S/OL]. (1938-01-25)[2014-10-27]. http://www.gpo.gov/fdsys/pkg/USCODE-2010-title21/html/USCODE-2010-title21-chap9-subchapV-partA-sec351.htm.
[3] Federal Food, Drug, and Cosmetic Act (FD&C Act). Chapter III§303. Penalties[S/OL].(1938-01-25)[2014-10-27].http://www.gpo.gov/fdsys/pkg/USCODE-2010-title21/html/USCODE-2010-title21-chap9-subchapIII-sec333.htm.
[4] EDQM. Council of Europe Convention on the counterfeiting of medical products and similar crimes involving threats to public health[S/OL].(2011-10-28)[2014-10-27]. http://conventions.coe.int/Treaty/EN/Treaties/Html/211.htm.
[5] EMA. Directive 2011/62/EU of The European Parliament And of The Council of 8 June 2011[S/OL].(2011-07-08)[2014-10-27]. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:174:0074:0087:EN:PDF.
[6] EMA. Directive 2011/62/EU of The European Parliament And of The Council of 8 June 2011[S/OL].(2011-07-08)[2014-10-27].http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:174:0074:0087:EN:PDF.
[7] The United Kingdom Parliament. Medicines Act[S/OL].Part III.(1968)[2014-10-27].http://www.legislation.gov.uk/ukpga/1968/67/section/63.
[8] EMA. Council Directive of 25 July 1985(85/374/EEC).Article 6 [S/OL].(1985-07-25)[2014-10-27].http://www.docin.com/p-334399313.html.
[9] 董春华.中美产品缺陷法律制度基本问题比较研究[D].北京: 中国政法大学, 2009.
[10] 许传玺.侵权法重述第三版,产品责任[M].法律出版社，2006：206.
[11] MHRA. A Guide to Defective Medicinal Products.[S/OL].[2014-
10-27].http://www.mhra.gov.uk/home/groups/is-lic/documents/
publication/con007572.pdf.
[12] 赵蓓, 王准, 宋民宪. 药品警示缺陷概念分析[J]. 中药与临床, 2013(2):56-58.

[1]	马美英, 赵晓佩, 张梦瑶, 胡一琳. 我国药品追溯码编码制度研究探讨[J]. 中国药物警戒, 2024, 21(2): 167-172.
[2]	朱盈, 沈璐, 李岚, 吴建民, 高晓洁. 新法规体系下我国牙膏不良反应监测工作分析与思考[J]. 中国药物警戒, 2024, 21(2): 219-222.
[3]	刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.
[4]	田春华, 吴桂芝. 定期获益-风险评估报告在我国的实施思考[J]. 中国药物警戒, 2023, 20(12): 1382-1384.
[5]	赵燕, 李尧, 宋雅娜, 郑立佳, 李栋, 赵一飞, 卞蓉蓉, 董放. 警戒视域下开展医疗器械上市后主动监测的实践研究与思考[J]. 中国药物警戒, 2023, 20(12): 1385-1390.
[6]	逄瑜, 刘博, 吴文宇, 田月洁, 王涛. 英国患者报告制度建立的浅析与启示[J]. 中国药物警戒, 2023, 20(11): 1259-1263.
[7]	夏旭东, 黎美霞, 孙阳, 杨胜亚. 药品上市许可持有人药物警戒远程检查流程探讨[J]. 中国药物警戒, 2023, 20(9): 967-970.
[8]	仉琪, 陈敏, 张世庆. 美国医疗器械附条件批准介绍及启示[J]. 中国药物警戒, 2023, 20(9): 1007-1010.
[9]	聂晓璐, 唐少文, 喻锦扬, 宋海波, 符祝, 孙凤. 药品风险最小化评价研究报告规范解读[J]. 中国药物警戒, 2023, 20(5): 524-529.
[10]	赵燕, 刘文博, 赵一飞, 李栋, 郑立佳, 宋雅娜, 赵玉娟, 董放. 患者登记研究应用于医疗器械监管科学的实践研究与思考[J]. 中国药物警戒, 2023, 20(4): 423-427.
[11]	崔欢欢, 裴小静, 李艳蓉, 刘文东, 王海学, 蓝恭涛, 王涛. 我国临床试验期间药物警戒工作实践与思考[J]. 中国药物警戒, 2022, 19(10): 1050-1054.
[12]	沙明泉, 李楠楠, 夏文静, 魏群, 温宝书. 美国FDA监管科学研究进展及启示[J]. 中国药物警戒, 2022, 19(10): 1055-1059.
[13]	张雅娟, 江阳. 韩国药物警戒体系介绍及启示[J]. 中国药物警戒, 2022, 19(10): 1082-1086.
[14]	赵一飞, 赵燕, 董放, 郑立佳, 李栋, 宋雅娜. 国际医疗器械监管机构论坛患者登记项目指南介绍与启示[J]. 中国药物警戒, 2022, 19(10): 1091-1096.
[15]	白荷荷, 聂晓静, 夏丽, 马莉, 王金萍, 彭莉蓉. 基于中国医院药物警戒系统开展药品不良反应监测的效果评价[J]. 中国药物警戒, 2022, 19(10): 1136-1139.